Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.73% of ...
CantorFitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($6.11) per share for the year, up from their previous estimate of ($6.21).
Small caps’ (NYSEARCA:IWM), (SP600) outperformance should continue into the year-end, according to Eric Johnston, senior managing director at CantorFitzgerald, in a bi-weekly report.
CantorFitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 100%.